Thomson, Benjamin R.
Liu, Pan
Onay, Tuncer http://orcid.org/0000-0001-8891-2300
Du, Jing
Tompson, Stuart W. http://orcid.org/0000-0001-9788-6730
Misener, Sol
Purohit, Raj R. http://orcid.org/0000-0002-7227-2959
Young, Terri L. http://orcid.org/0000-0001-6994-9941
Jin, Jing
Quaggin, Susan E. http://orcid.org/0000-0002-3706-5727
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Eye Institute (R01 EY014685, P30 EY016665, R01 EY025799)
U.S. Department of Health & Human Services | NIH | National Eye Institute
Research to Prevent Blindness Lew R. Wasserman Award
U.S. Department of Health & Human Services | NIH | National Eye Institute
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01 HL124120)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK114857)
Article History
Received: 11 July 2020
Accepted: 30 September 2021
First Online: 18 October 2021
Competing interests
: The authors declare the following competing interests: S.E.Q. is an inventor of patents related to therapeutic targeting of the ANGPT-TEK pathway in ocular hypertension and glaucoma and owns stock in and is a director of Mannin Research. S.E.Q. also receives consulting fees from AstraZeneca, Janssen, the Lowy Medical Research Foundation, and Roche/Genentech; is Chair of the External Scientific Advisory Board for AstraZeneca; and is a scientific advisor or member of AstraZeneca, Genentech/Roche, the Karolinska CVRM Institute, the Lowy Medical Research Institute, Mannin, and Novartis. J.J. has applied for a patent related to the ANGPT1 mimetic compound described in the article. In addition, he is a scientific advisor for Mannin Research and QBioMed. T.L.Y. serves as a consultant to Aerpio Pharmaceuticals. The other authors declare no competing interests.